The analysis of total serum IgE, Phadiatop and fx5 tests in chronic rhinosinusitis patients with nasal polyps
Article Sidebar
Main Article Content
Abstract
The purpose of the study: 1. To compare levels of total serum IgE of chronic rhinosinusitis patients with nasal polyps and healthy volunteers. 2. To estimate percentage of nasal polyposis patients with positive Phadiatop and fx5 tests. 3. To determine if the presence of IgE-dependent allergy has an influence on the clinical picture of nasal polyposis.
Material: 67 patients with nasal polyps and 36 healthy volunteers (control group - Z) were included into the study. Patients with nasal polyps were divided into three groups: PP - primary polyps (without lower airways diseases), n=33; A - polyps and bronchial asthma (without aspirin sensitivity), n=19; ASA - polyps and aspirin sensitive asthma, n=15.
Methods: In all subjects concentration of total serum IgE, using Pharmacia CAP System IgE FEIA was measured. In patients with nasal polyps Phadiatop test (screening test for diagnosing inhalant allergy) and fx5 test (screening test for diagnosing food allergy), using Pharmacia CAP System Phadiatop FEIA and Pharmacia CAP System fx5 were performed. The correlation analysis between some features of clinical picture of nasal polyps and atopy coexistence were performed.
Results: Median value of total serum IgE concentrations in nasal polyps was 79,1 kU/l (value range from 4,11 to 2000 kU/l); in PP group – 77,0 kU/l, in A group – 96,8 kU/l; in ASA group – 66,6 kU/l and in control group (healthy volunteers) – 39,0 kU/l (range: 14,0–120 kU/l). 30.3% cases of patients with nasal polyps had the total serum IgE concentration higher than 150 kU/l, but we did not find any statistical differences between all studied groups (PP, A, ASA and control group). Although we noticed some tendency to occur a bit higher values of total Ig-E among patients with nasal polyps, comparing to healthy subjects. The positive results of Phadiatop test in patients with nasal polyps were noted in 28% cases and positive fx5 test in 10% of nasal polyposis patients. We did not find any differences between nasal polyps groups in the results of Phadiatop test (p=0,29) and fx5 test (p=0,19). History taking of the nasal polyp patients indicated atopy only in 10,5% of cases. We did not find any correlation between the coexistence of atopy and number of recurrences of nasal polyps, the duration of nasal polyps and the age of onset of nasal polyps.
Conclusions: Although we found elevated values of total serum IgE in some patients with nasal polyps as well as positive results of Phadiatop and fx5 tests, IgE-dependent allergy only seems to coexist in some cases with nasal polyps. The latest epidemiological data indicate that allergic diseases affect 16–45% of population in European countries. So that is the next evidence that atopy in nasal polyps patients is
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Bachert C., Gevaert P., Holtappels G. et al.: Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J. Allergy Clin. Immunol. 2001, 107: 607-614.
3. Oberritter H., Bock S.A., Foucard T., Hattevig G., Åberg N., Varjonen E., Haahtela T., Heinonen O.P., Bakke P.: Allergy Guide, Kabi Pharmacia Diagnostics. Sparre Medical, Bohlins Grafiska 1993.
4. Mygind N., Dahl R., Pedersen S., Thestrup-Pedersen K.: Essential Allergy. Blackwell Science Ltd, Oxford 1996.
5. Jang T.Y., Cho C., Yun Y.S.: Local production of IgE in nasal polyps. Am. J. Rhinology 1997, 11: 413-414.
6. Merrett T.G.: Quantification of IgE both as total immunoglobulin and as allergen-specific antibody. W: Allergy and allergic disease. Kay A.B. (red.). Blackwell Science, Oxford London, Edinburgh, 1997: 1012-1031.
7. Zawisza E., Rzepkowska M.: Immunoglobulina E. W: Choroby alergiczne. Zawisza E., Samoliński B. (red.). PZWL, Warszawa, 1998: 37-42.
8. Burney P., Malmberg E., Chinn S., Jarvis D., Luczynska C., Lai D.: The distribution of total and specific serum IgE in the European Community Respiratory Health Survey. J. Allergy Clin. Immunol. 1997, 99: 314-322.
9. Howarth P.H.: Is allergy increasing? - early life influence. Clin. Exp. Allergy 1998, 28 (suppl.6): 2-7.
10. Samoliński B.K.: Epidemiologia alergicznego nieżytu nosa w Polsce. XI Konferencja Naukowo-Szkoleniowa Alergologów, Pulmunologów i Immunologów Klinicznych, Wschodnie Spotkania Alergologiczno-Immunologiczne, Ryn, 2–4 października 2008.
11. Krajina Z.: Etipathogenesis of nasal polyps. Acta Med. Croatica 1993, 47: 81-84.
12. Settipane G.A.: Nasal polyps and immunoglobulin E (IgE). W: Nasal Polyps: epidemiology, pathogenesis and treatment. Settipane G.A., Lund V.J., Bernstein J.M., Tos M. (red.). OceanSide Publication, Inc, Providence, Rhode Island 1997: 105-109.
13. Settipane G.A., Chafee F.H.: Nasal polyps in asthma with rhinitis: a review of 6037 patients. J. Allergy Clin. Immunol. 1977, 59: 17-21.
14. Caplin I., Hynes T.J., Spahn J.: Are nasal polyps an allergic phenomenon? Ann. Allergy 1971, 29: 631-634.
15. Granström G., Jacobsson E., Jeppsson P.H.: Influence of allergy, asthma and hypertension on nasal polyposis. Acta Otolaryngol. (Stockh.), 1992, 492 (suppl.): 22- 27.
16. Pastorello E.A., Incorvaia C., Riario-Sforza G.G., Codecasa L., Menghisi V., Bianchi C.: Importance of allergic etiology in nasal polyposis. Allergy Proc. 1994, 15: 151-155.
17. Bochenek G., Niżankowska E., Szczeklik A.: The prevalence of atopy in patients with intolerance to nonsteroidal antiinflamatory drugs (NSAIDS). Eur. Respir J. 1993, 6 (suppl. 17): 333.
18. Settipane G.A., Settipane R.A.: Nasal polyps and aspirin intolerance. W: Nasal Polyps: epidemiology, pathogenesis and treatment. Settipane G.A., Lund V.J., Bernstein J.M., Tos M. (red.). OceanSide Publication, Inc, Providence, Rhode Island 1997: 111-117.
19. Pacor M.L., Santoni P., Nicolis F., Peroli P., Biasi D., Cortina P., Marchi G., Lunardi C.: Nasal polyps and food intolerance: is there any correlation. Recenti Progressi in Medicina 1989, 80: 434-437.
20. Klossek J.M., Neukirch F., Pribil C. et al.: Prevalence of nasal polyposis in France: a cross-sectional, case-control study. Allergy 2005, 60: 233-237.
21. Rugina M., Serrano E., Klossek J.M., Crampette L., Stoll D., Bebear J.P. et al.: Epidemiological and clinical aspects of nasal polyposis in France, the ORLI group experience. Rhinology 2002, 40: 75-79.
22. Pang Y.T., Eskici O., Wilson J.A.: Nasal polyposis: role of subclinical delayed food hypersensitivity. Otolaryngol. Head Neck Surg. 2000, 122: 298-301.
23. Frew A.J.: Skin tests. W: Allergy and allergic disease. Kay A.B. (red.). Blackwell Science, Oxford, London, Edinburgh, 1997: 1007-1011.
24. Keith P., Dolovich J.: Allergy and nasal polyps. W: Nasal Polyposis. An inflammatory disease and its treatment. Mygind N., Lildholdt T. (red.). Munksgaard, Copenhagen 1997: 68-77